An open-label exploratory study evaluating the efficacy and safety of ingenol mebutate gel 0.05% for the treatment of verruca vulgaris


10 Apr 2018 04:37 Ricerca


Current therapies for common warts (verruca vulgaris) often require months of treatment and focus on destruction, removal of callus, or stimulation of a local immune response. Topical use of ingenol mebutate gel, 0.05%, indicated for the treatment of actinic keratosis, induces necrosis and an inflammatory reaction. A recent case study series provided evidence for the efficacy of ingenol mebutate against anogenital warts.

Neal D. Bhatia, MD

JAAD March 2018 Volume 78, Issue 3, Pages 595-596

Inserito da segreteria SIDeMaST